Phase III results offer hope for two-drug HIV treatment regimen

20 December 2016

ViiV Healthcare has announced that both of its Phase III studies to evaluate the safety and efficacy of switching virologically suppressed patients from a three or four-drug antiretroviral regimen to a two-drug regimen of Tivicay (dolutegravir) and Edurant (rilpivirine) met the primary endpoint of non-inferiority at week 48.

The HIV specialist, which is majority-owned by UK pharma major GlaxoSmithKline (LSE: GSK), with Pfizer Inc and Shionogi Limited as shareholders, is developing dolutegravir while rilpivirine belongs to Janssen Sciences Ireland, one of the Janssen Pharmaceutical companies of US health care giant Johnson & Johnson (NYSE: JNJ).

"We are planning regulatory submissions for this two-drug regimen as a single tablet in 2017"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK